IP Library Granted Patent US 8,329,220
Granted Patent B2
US 8,329,220 · App. 12/197,179 · Granted Dec 11, 2012

Controlled release formulations

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,329,220
App. No.
12/197,179
Granted
Dec 11, 2012
Kind
B2
Abstract

The present invention provides stable, self-assembling, biocompatible and biodegradable hydrogel formulations, into which one or more compounds may be incorporated allowing for delayed release or controlled release of the incorporated compounds as the hydrogel is degraded in the body.

Claims (16)

1. A buffered hydrogel comprising:

a) a therapeutic agent;

b) a sucrose ester, wherein the sucrose ester is a combination of sucrose stearate and sucrose distearate; and

c) a buffer,

wherein the hydrogel is formed by heat treatment of a suspension of (a)-(c) at temperatures of 37-45° C.

2. The hydrogel of claim 1 , further comprising a preservative.

3. The hydrogel of claim 2 , wherein the preservative is ethylene diamine tetraacetic acid (EDTA), benzalkonium chloride, sodium azide or dodecyl maltoside.

4. The hydrogel of claim 1 , wherein the hydrogel has a pH from 4 to 8.

5. The hydrogel of claim 1 , wherein the hydrogel has a pH from 4.5 to 6.5.

6. The hydrogel of claim 1 , wherein the therapeutic agent is a peptide, hormone, steroid, anti-inflammatory, anti-biotic, anti-viral, UV blocker, or anti-wrinkle agent.

7. The hydrogel of claim 6 , wherein the agent is an anti-wrinkle agent selected from the group consisting of: retinol, retinoic acid, 13-trans retinoic acid, 13-cis retinoic acid, retinyl ester, hydroxy acid, alpha hydroxy acid, beta hydroxy acid, poly hydroxy acid, glycolic acid, lactic acid, an exfoliant, a Coenzyme Q10 copper peptide, a kinetin, a tea extract, and a collagen.

8. The hydrogel of claim 6 , wherein the steroid is testosterone.

9. The hydrogel of claim 6 , wherein the peptide is thymosin β-4.

10. The hydrogel of claim 6 , wherein the buffer is an acetate buffer.

11. The hydrogel of claim 6 , wherein the buffer is a citrate buffer.

12. The hydrogel of claim 6 , wherein the therapeutic agent is uniformly distributed throughout the hydrogel.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Nov 14, 2024
From: ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP
To: NEURELIS, INC.; AEGIS THERAPEUTICS, LLC
Reel/Frame 069359/0921 →
SECURITY INTEREST Recorded Aug 6, 2021
From: NEURELIS, INC.; AEGIS THERAPEUTICS, LLC
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP
Reel/Frame 057111/0242 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2008
From: MEEZEN, ELIAS; PILLION, DENNIS J.; MORGAN, SARAH L.; BAGGOTT, JOE
To: THE UAB RESEARCH FOUNDATION
Reel/Frame 021755/0547 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2008
From: MAGGIO, EDWARD T.
To: AEGIS THERAPEUTICS, LLC
Reel/Frame 021755/0582 →